Norovirus GII.17 accounted for < 10% of outbreaks in the US 2022-23 season, but rose to 75% during the 2024-25 season, passing the number of GII.4 outbreaks.

Vaxart (NASDAQ:VXRT) stock jumped 37.9% premarket after the company reported positive early-stage data for its second-generation oral norovirus vaccine pill, with antibody responses up 141% ...

– Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation ...

2.9 Cross-reactivity between GII.11 and GI.3, GII.6 and GII.17 sera from NoV-infected patients To further evaluate the cross-reactivity of the GII.11 NoV-LISA in authentic infection scenarios, six ...

It is winter, and a new strain of norovirus called GII.17[P17] is spreading across the U.S. including the northeast. MedStar Health Urgent Care in our region is experiencing an uptick in norovirus ...

With the decrease of GII.4 outbreaks since 2024, whether GII.17 viruses will continue to cause an earlier onset of the norovirus season cannot yet be determined," the CDC researchers wrote.

We aren't quite clear of peak norovirus season just yet, and if you come down with the debilitating virus, the symptoms could linger in your system for some time. Here's what you need to know if ...

The rare condition is called Boerhaave syndrome, defined as a life-threatening, spontaneous rupture of the esophagus ...

The Centers for Disease Control and Prevention reported 91 norovirus outbreaks during the week of Dec. 5, 2024; a 32% increase compared to the previous week, DPHSS said.

What You Need To Know A multistate norovirus outbreak has been linked to raw oysters from Texas, the Centers for Disease Control and Prevention announced The CDC said as of Thursday, 211 illnesses ...

Millions of kids have now been vaccinated against rotavirus. Norovirus, by contrast, is famous as the scourge of cruise ships, making hundreds of guests suffer through stomach pain and diarrhea.

Vaxart, Inc., a biotechnology company focused on oral recombinant pill vaccines, announced it will release topline data from its Phase I trial on norovirus before the market opens on June 11, 2025.